BackTaro Pharmaceutical Industries Overview
Taro Pharmaceutical Industries

Taro Pharmaceutical Industries P/E Ratio

Valuation check: TARO's P/E ratio is 30.05, above the Healthcare sector average of 21.65.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

30.05

P/E Ratio

30.05

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Taro Pharmaceutical Industries (TARO) FAQ

The latest P/E ratio for TARO is 30.05. That is above the Healthcare sector average of 21.65. Investors often review this figure alongside Taro Pharmaceutical Industries's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, TARO currently prints 30.05 for P/E ratio, while the sector average sits near 21.65. That is roughly 38.8% above the sector mean. Large gaps often invite a closer look at Taro Pharmaceutical Industries's growth, margins, and balance sheet.

A P/E ratio of 30.05 for Taro Pharmaceutical Industries is not 'good' or 'bad' on its own. Compare it with the peer average (21.65) and with TARO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting TARO's P/E ratio (30.05), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Taro Pharmaceutical Industries's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.